Chemicals · Founded 1972 · www.paushak.com · BSE 532742 · NSE PAUSHAKLTD · ISIN INE111F01024
No Notes Added Yet
Business
Paushak Ltd. is an Indian chemical company primarily engaged in the manufacturing of specialty chemicals. While specific product details require access to their latest reports, companies in this sector typically focus on niche and complex chemistries, often serving as critical intermediates or performance additives for various industries. Their core business model involves large-scale manufacturing and supply of these specialized chemical products, predominantly on a business-to-business (B2B) basis, to sectors such as agrochemicals, pharmaceuticals, polymers, or other industrial applications. The company generates revenue by selling these manufactured specialty chemical products to its industrial clients.
Revenue Mix
Without access to specific financial reports, detailed segment breakdown is not publicly available. However, based on its "Chemicals" sector classification, Paushak Ltd. likely operates primarily within the specialty chemicals domain. This often involves distinct product lines that cater to different end-user industries (e.g., fluorochemicals, custom synthesis for pharmaceuticals, agrochemical intermediates, or performance chemicals). The revenue mix would be driven by the sales volume and pricing of these specialized products across its customer base.
Industry
The Indian chemicals industry is diverse, encompassing both commodity and specialty chemicals. Paushak Ltd. operates in the specialty chemicals segment, which is generally characterized by higher value addition, complex manufacturing processes, and often higher barriers to entry compared to commodity chemicals. The industry is competitive, with both domestic players and global companies having a presence. Paushak Ltd. likely positions itself as a reliable supplier with expertise in specific, complex chemistries, potentially focusing on niche applications or proprietary manufacturing processes. Its positioning would be against other specialty chemical manufacturers, both domestic and international, that cater to similar end-user industries.
MOAT
For a specialty chemical company like Paushak Ltd., competitive advantages often stem from:
Process Expertise: Developing and scaling up complex chemical reactions efficiently and safely.
R&D Capabilities: Ability to innovate, develop new products, or improve existing processes, leading to cost efficiencies or unique product offerings.
Customer Relationships & Switching Costs: For critical inputs, customers often face significant costs (re-qualification, testing) in switching suppliers, fostering long-term relationships.
Regulatory Compliance: Expertise in meeting stringent environmental, health, and safety standards, particularly for regulated industries like pharma and agrochemicals.
Growth Drivers
Key factors that could drive Paushak Ltd.'s growth over the next 3-5 years include:
"China Plus One" Strategy: Global companies diversifying supply chains away from China, leading to increased outsourcing and manufacturing opportunities for Indian chemical players.
Demand from End-User Industries: Sustained or growing demand from key sectors like agrochemicals (food security), pharmaceuticals (healthcare), and other industrial applications.
Capacity Expansion: Investment in new manufacturing capacities or debottlenecking existing ones to meet growing demand and expand market reach.
New Product Development: Successful R&D leading to the introduction of new, high-value specialty chemicals, opening up new market segments.
Import Substitution: Growing domestic demand allowing Indian manufacturers to substitute imports with locally produced chemicals.
Risks
Raw Material Price Volatility: Fluctuations in the prices of key feedstocks, many of which are crude oil derivatives or globally traded, can impact profitability.
Environmental & Regulatory Risks: Stringent environmental regulations and compliance costs, potential for plant shutdowns due to non-compliance, or changes in safety standards.
Intense Competition: Competition from domestic and international players can lead to pricing pressure and margin erosion.
Global Economic Slowdown: A downturn in the global economy can reduce demand from end-user industries.
Technological Obsolescence: Failure to keep pace with new technologies or greener chemistry processes.
Capital Intensity: The chemical manufacturing business is capital-intensive, requiring continuous investment in plant and machinery.
Management & Ownership
Paushak Ltd. is part of the Alembic Group, a well-established industrial conglomerate in India, indicating a strong promoter background. Typically, such companies have a promoter-driven management structure, often with professional executives overseeing day-to-day operations. The quality of management would hinge on their technical expertise in chemistry, strategic vision for growth, operational efficiency, and commitment to corporate governance. The ownership structure generally involves a significant stake held by the promoter group, with the remaining shares held by institutional investors, high-net-worth individuals, and the public.
Outlook
Paushak Ltd. operates in the specialty chemicals sector, an area with significant growth potential, particularly given the "China Plus One" global supply chain diversification trend and robust demand from key end-user industries like pharma and agrochemicals. The company's established presence within the Alembic Group provides a foundation of experience and resources. However, the business is capital-intensive, susceptible to raw material price volatility, and subject to evolving environmental regulations. Its future performance will largely depend on its ability to innovate new products, expand capacity efficiently, manage operational costs effectively, and navigate the competitive landscape while adhering to stringent compliance standards.
| #(Fig in Cr.) | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 52 | 57 | 49 | 52 | 56 | 59 | 49 | 55 | 84 | 89 |
| Other Income | 4 | 4 | 6 | 0 | 2 | 1 | 1 | 8 | 3 | 2 |
| Total Income | 56 | 61 | 56 | 52 | 58 | 60 | 50 | 63 | 87 | 91 |
| Total Expenditure | 40 | 40 | 35 | 36 | 38 | 44 | 37 | 38 | 58 | 63 |
| Operating Profit | 16 | 21 | 21 | 16 | 20 | 16 | 12 | 25 | 29 | 28 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 17 | 17 | 12 | 16 | 11 | 7 | 16 | 19 | 19 |
| Provision for Tax | 2 | 3 | 2 | 3 | 4 | 3 | 1 | 4 | 4 | 5 |
| Profit After Tax | 10 | 14 | 15 | 10 | 12 | 9 | 6 | 13 | 15 | 14 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 10 | 14 | 15 | 10 | 12 | 9 | 6 | 13 | 15 | 14 |
| Adjusted Earnings Per Share | 4.2 | 5.8 | 6.2 | 3.9 | 4.9 | 3.5 | 2.5 | 5.1 | 6.1 | 5.5 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 78 | 67 | 103 | 140 | 138 | 141 | 150 | 212 | 206 | 211 | 219 | 277 |
| Other Income | 3 | 5 | 3 | 3 | 5 | 6 | 5 | 9 | 20 | 14 | 12 | 14 |
| Total Income | 81 | 72 | 106 | 142 | 143 | 147 | 155 | 221 | 227 | 225 | 231 | 291 |
| Total Expenditure | 61 | 55 | 74 | 99 | 95 | 91 | 96 | 137 | 142 | 151 | 158 | 196 |
| Operating Profit | 19 | 17 | 32 | 43 | 47 | 57 | 59 | 84 | 85 | 74 | 73 | 94 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Depreciation | 3 | 3 | 3 | 4 | 4 | 5 | 9 | 13 | 14 | 15 | 21 | 29 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 10 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 17 | 14 | 29 | 49 | 45 | 52 | 50 | 72 | 71 | 59 | 50 | 61 |
| Provision for Tax | 4 | 3 | 7 | 10 | 10 | 14 | 13 | 18 | 17 | 9 | 11 | 14 |
| Profit After Tax | 12 | 11 | 21 | 39 | 35 | 37 | 38 | 54 | 54 | 49 | 39 | 48 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 12 | 11 | 21 | 39 | 35 | 37 | 38 | 54 | 54 | 49 | 39 | 48 |
| Adjusted Earnings Per Share | 4.8 | 4.3 | 8.4 | 15.8 | 14.2 | 15.1 | 15.3 | 21.9 | 22 | 20 | 15.9 | 19.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 4% | 1% | 9% | 11% |
| Operating Profit CAGR | -1% | -5% | 5% | 14% |
| PAT CAGR | -20% | -10% | 1% | 13% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -8% | -4% | -12% | 24% |
| ROE Average | 8% | 11% | 13% | 16% |
| ROCE Average | 10% | 14% | 16% | 21% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 69 | 83 | 113 | 178 | 227 | 272 | 306 | 354 | 408 | 465 | 491 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 60 |
| Other Non-Current Liabilities | 2 | 4 | 9 | 22 | 26 | 30 | 34 | 39 | 47 | 37 | 43 |
| Total Current Liabilities | 11 | 7 | 22 | 15 | 16 | 27 | 27 | 22 | 26 | 44 | 65 |
| Total Liabilities | 82 | 94 | 144 | 214 | 270 | 329 | 367 | 415 | 481 | 572 | 660 |
| Fixed Assets | 20 | 35 | 37 | 38 | 41 | 51 | 147 | 149 | 152 | 141 | 377 |
| Other Non-Current Assets | 22 | 33 | 52 | 86 | 119 | 183 | 116 | 119 | 113 | 331 | 152 |
| Total Current Assets | 40 | 26 | 56 | 90 | 111 | 95 | 104 | 147 | 216 | 100 | 132 |
| Total Assets | 82 | 94 | 144 | 214 | 270 | 329 | 367 | 415 | 481 | 572 | 660 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| Cash Flow from Operating Activities | 14 | 12 | 10 | 24 | 45 | 30 | 44 | 43 | 56 | 38 | 54 |
| Cash Flow from Investing Activities | -13 | -11 | -10 | -0 | -43 | -29 | -42 | -38 | -50 | -57 | -95 |
| Cash Flow from Financing Activities | -1 | -2 | -1 | -23 | -2 | -2 | -2 | -4 | -5 | 19 | 42 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 0 | 0 | -1 | -0 | 0 | 0 | -1 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.84 | 4.26 | 8.37 | 15.8 | 14.16 | 15.13 | 15.25 | 21.9 | 22.04 | 20.03 | 15.95 |
| CEPS(Rs) | 5.93 | 5.52 | 9.69 | 17.37 | 15.94 | 17.14 | 18.91 | 27.34 | 27.66 | 26.1 | 24.62 |
| DPS(Rs) | 0.38 | 0.38 | 0.38 | 0.63 | 0.75 | 0.75 | 1.5 | 2.19 | 2.5 | 2.5 | 2.5 |
| Book NAV/Share(Rs) | 26.76 | 32.36 | 44.09 | 72.01 | 92.16 | 110.18 | 123.93 | 143.45 | 165.52 | 188.79 | 199.18 |
| Core EBITDA Margin(%) | 20.02 | 16.75 | 28.02 | 28.81 | 31.01 | 35.79 | 36.13 | 35.41 | 31.27 | 28.28 | 27.81 |
| EBIT Margin(%) | 19.91 | 19.6 | 27.65 | 35.21 | 32.96 | 36.62 | 33.54 | 34.16 | 34.49 | 27.93 | 23.57 |
| Pre Tax Margin(%) | 19.84 | 19.52 | 27.56 | 35.12 | 32.9 | 36.59 | 33.5 | 34.01 | 34.42 | 27.86 | 23.06 |
| PAT Margin (%) | 14.83 | 15.13 | 20.5 | 27.93 | 25.32 | 26.45 | 25.06 | 25.43 | 26.35 | 23.41 | 17.99 |
| Cash Profit Margin (%) | 18.18 | 19.57 | 23.73 | 30.7 | 28.49 | 29.97 | 31.07 | 31.75 | 33.06 | 30.5 | 27.77 |
| ROA(%) | 16.52 | 12.43 | 17.99 | 21.73 | 14.43 | 12.46 | 10.82 | 13.83 | 12.13 | 9.38 | 6.38 |
| ROE(%) | 19.7 | 14.43 | 21.89 | 26.8 | 17.25 | 14.95 | 13.03 | 16.38 | 14.27 | 11.3 | 8.22 |
| ROCE(%) | 26.29 | 18.63 | 29.44 | 33.73 | 22.45 | 20.7 | 17.44 | 22 | 18.68 | 13.11 | 9.74 |
| Receivable days | 92.19 | 93.68 | 95.95 | 93.12 | 77.61 | 76.49 | 88.33 | 79.25 | 91.28 | 91.01 | 91.32 |
| Inventory Days | 35.28 | 44.71 | 36.03 | 39.24 | 45.2 | 38.88 | 39.84 | 35.85 | 39.38 | 37.55 | 48.66 |
| Payable days | 96.33 | 94.23 | 108.65 | 95.87 | 98.56 | 132.67 | 181.06 | 134.15 | 127.37 | 149.54 | 202.64 |
| PER(x) | 15.28 | 16.97 | 19.22 | 16.04 | 15.27 | 69.06 | 85.18 | 35.48 | 28.91 | 28.19 | 21.67 |
| Price/Book(x) | 2.76 | 2.24 | 3.65 | 3.52 | 2.35 | 9.48 | 10.48 | 5.42 | 3.85 | 2.99 | 1.74 |
| Dividend Yield(%) | 0.51 | 0.52 | 0.23 | 0.25 | 0.35 | 0.07 | 0.12 | 0.28 | 0.39 | 0.44 | 0.72 |
| EV/Net Sales(x) | 2.44 | 2.78 | 3.99 | 4.47 | 3.86 | 18.26 | 21.34 | 9.02 | 7.61 | 6.72 | 4.25 |
| EV/Core EBITDA(x) | 9.75 | 10.66 | 12.76 | 14.57 | 11.22 | 45.5 | 53.96 | 22.73 | 18.48 | 19.17 | 12.73 |
| Net Sales Growth(%) | 12.91 | -14.42 | 55.14 | 34.89 | -1.15 | 2.24 | 6.45 | 41.47 | -2.87 | 2.27 | 3.63 |
| EBIT Growth(%) | -7.52 | -14.96 | 104.3 | 69.61 | -7.48 | 13.62 | -2.52 | 44.09 | -1.92 | -17.19 | -12.54 |
| PAT Growth(%) | -4.43 | -11.88 | 96.22 | 81.44 | -10.38 | 6.83 | 0.84 | 43.59 | 0.64 | -9.15 | -20.36 |
| EPS Growth(%) | -4.43 | -11.88 | 96.22 | 88.8 | -10.38 | 6.83 | 0.84 | 43.59 | 0.64 | -9.16 | -20.36 |
| Debt/Equity(x) | 0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.16 |
| Current Ratio(x) | 3.61 | 3.69 | 2.49 | 6.07 | 6.81 | 3.49 | 3.83 | 6.6 | 8.3 | 2.24 | 2.01 |
| Quick Ratio(x) | 2.78 | 2.48 | 1.95 | 4.86 | 5.81 | 2.98 | 3.13 | 5.58 | 7.46 | 1.75 | 1.45 |
| Interest Cover(x) | 276.45 | 239.88 | 295.24 | 360.16 | 592.57 | 1051.69 | 818.52 | 233.3 | 467.13 | 416.35 | 46.25 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.09 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.97 | 66.97 | 66.97 | 67.13 | 67.13 | 67.28 | 67.28 | 67.28 | 67.28 | 67.28 |
| FII | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0.11 |
| DII | 0.29 | 0.34 | 0.4 | 0.53 | 0.53 | 0.71 | 0.67 | 0.25 | 0.07 | 0.27 |
| Public | 32.74 | 32.69 | 32.64 | 32.32 | 32.33 | 32.01 | 32.05 | 32.47 | 32.65 | 32.34 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 1.66 | 1.66 | 1.66 | 1.66 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.01 | 0 | 0.01 |
| Public | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.79 | 0.8 | 0.81 | 0.8 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 2.47 | 2.47 | 2.47 | 2.47 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +4% | +1% | +9% | +11% |
| Operating Profit CAGR | -1% | -5% | +5% | +14% |
| PAT CAGR | -20% | -10% | +1% | +13% |
| Share Price CAGR | -8% | -4% | -12% | +24% |
| ROE Average | +8% | +11% | +13% | +16% |
| ROCE Average | +10% | +14% | +16% | +21% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.97 | 66.97 | 66.97 | 67.13 | 67.13 | 67.28 | 67.28 | 67.28 | 67.28 | 67.28 |
| FII | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0.11 |
| DII | 0.29 | 0.34 | 0.4 | 0.53 | 0.53 | 0.71 | 0.67 | 0.25 | 0.07 | 0.27 |
| Public | 32.74 | 32.69 | 32.64 | 32.32 | 32.33 | 32.01 | 32.05 | 32.47 | 32.65 | 32.34 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 1.66 | 1.66 | 1.66 | 1.66 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.01 | 0 | 0.01 |
| Public | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.79 | 0.8 | 0.81 | 0.8 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 2.47 | 2.47 | 2.47 | 2.47 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.